Current guidelines for managing mild, persistent asthma recommend inhaled corticosteroids as first-line therapy. However,
long-term use of these agents in high doses may cause adverse effects that require alternate strategies, including low-dose,
once-daily inhaled corticosteroids and oral regimens that do not use corticosteroids. Two recently published trials, the Leukotriene
or Corticosteroid or Corticosteroid-Salmeterol trial and the Beclomethasone plus Salbutamol Treatment multinational trial,
describe the effects of these approaches.